Clinical Psychiatry News - Drug approved for Parkinson’s
Requip XL (ropirinole extended release tablets) have been approved by the Food and Drug Administration for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. It is the first and only oral once-daily non-ergot dopamine agonist that is indicated for Parkinson’s. For more information, visit www.requipxl.com.
Related Results
Requip for RLSRequip reduces risk of dyskinesiasRequip now has generic competitorsGSK’s Requip significantly improves restless legs syndromeRequip shows use for restless legs syndrome.
COPYRIGHT 2008 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
